Metformin, SUs, meglitinides, alpha-glucosidase inhibitors, TZDs, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors may be used in patients with compensated liver cirrhosis; however, patients treated with metformin and DPP-4 inhibitors must be monitored for cirrhotic decompensation, those treated with TZDs need to be monitored for cardiovascular events, and those treated with SUs and meglitinides must be initially prescribed low doses to avoid hypoglycemia. The gene discussed is GLP1R; the disease is Hypoglycemia.